Midatech Pharma has widened its H1 pretax loss of £9.6m, from a year-earlier loss £5.3m. Revenue was £3.5m, from £121,000.
"Midatech has made good performance in the first half of 2016 and our commercial business is well placed to deliver continued revenue growth in the second half of 2016," said CEO Jim Philips.
"We continue to carefully invest in our platform technologies and candidate pipeline and the remainder of 2016 with 2017 are set to deliver results from a variety of our exciting R&D programmes," he said in a statement.
"Notwithstanding the challenging recent market conditions globally, we continue to look at opportunities to build value for shareholders and look to the future with optimism."